| CAS NO: | 2023788-19-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Name: Tirzepatide (LY-3298176) CAS#: 2023788-19-2 Formula: C225H348N48O68; C225H348N48O68.F3COOH (TFA);C225H348N48O68 HCL (HCL); C225H348N48O68 CH3COOH (acetate) Exact mass: 4810.5249 Mol weight: 4813.4514; 4927.4714(TFA); 4849.9514 (HCL) ; 4873.5014 (Acetate)Sequence: YXEGTFTSDY SIXLDKIAQK AFVQWLIAGG PSSGAPPPS In Vivo Formulation Method 1: Tirzepatide was formulated in 20 mM tris HCl buffer pH 8. Mice (n = 5–10 per treatment) were subcutaneously dosed (10 mL/kg) with the vehicle or peptides and immediately fasted overnight, followed 17 hours later by an intraperitoneal bolus of 2 g glucose/kg (intraperitoneal glucose tolerance test). Reference: Diabetes Obes Metab. 2020 Oct;22(10):1886-1891. In Vivo Formulation Method 2: Tirzepatide was solubilized in PBS. Reference: Mol Metab. 2018 Dec; 18: 3–14. | |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Technical Information | LY-3298176; LY 3298176; tirzepatide; LY3298176; |
In Vivo Formulation Method 1: Tirzepatide was formulated in 20 mM tris HCl buffer pH 8. Mice (n = 5–10 per treatment) were subcutaneously dosed (10 mL/kg) with the vehicle or peptides and immediately fasted overnight, followed 17 hours later by an intraperitoneal bolus of 2 g glucose/kg (intraperitoneal glucose tolerance test). Reference: Diabetes Obes Metab. 2020 Oct;22(10):1886-1891.
In Vivo Formulation Method 2: Tirzepatide was solubilized in PBS. Reference: Mol Metab. 2018 Dec; 18: 3–14.
m.cnreagent.com